AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT01127581
Drug: MVI 200
RxNorm normalized name: alpha-tocopherol acetate / ascorbic acid / biotin / dexpanthenol / ergocalciferol / folic acid / niacinamide / pyridoxine hydrochloride / riboflavin / thiamine hydrochloride / vitamin A / vitamin B12 / vitamin K1 Injectable Solution [MVI Pediatric]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose reservoir of 200 mcg of misoprostol in a hydrogel polymer vaginal insert within a retrieval system. The MVI 200 will be kept in place for up to 24 hours or will be removed earlier if one of the following occur: onset of active labor, intrapartum adverse event necessitating discontinuation of the study drug, other reasons including maternal request.
Trial: NCT01127581
Drug: Dinoprostone Vaginal Insert (DVI)
RxNorm normalized name: dinoprostone Vaginal Insert
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose reservoir of 10 mg of dinoprostone in a hydrogel polymer vaginal insert within a retrieval system. The DVI will be kept in place for up to 24 hours or will be removed earlier if one of the following occur: onset of active labor, intrapartum adverse event necessitating discontinuation of the study drug, other reasons including maternal request.
Trial: NCT01686828
Drug: Testosterone 1.62% gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal Testosterone Gel (either 1.25g or 5g/d) for 4 weeks
Trial: NCT01686828
Drug: Placebo gel (for Testosterone 1.62% gel)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo gel manufactured to mimic Testosterone 1.62% gel
Trial: NCT00261729
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo capsules
Trial: NCT03605706
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects receive placebo of SHR-1210 intravenous at the dose 3mg/kg on Day 1 every 2 weeks
Trial: NCT01197664
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given PO
Trial: NCT03179618
Drug: Anti-Platelet Drugs
RxNorm normalized name: platelet glycoprotein VI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Including aspirin and clopidogrel, etc.
Trial: NCT03179618
Drug: Lipid Regulating Drugs
RxNorm normalized name: guggul lipids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mainly including statins
Trial: NCT03179618
Drug: Coronary Vasodilator
RxNorm normalized name: Glebionis coronaria whole extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mainly including nitrates
Trial: NCT03179618
Drug: Xuefu Zhuyu Decoction
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mainly including Peach Kernel, Safflower, Angelica, Bupleurum etc.
Trial: NCT02916979
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Methotrexate:~Related donors: 5 mg/m2 on days 1, 3 and 6 Unrelated donors: 5 mg/m2 on days 1, 3, 6 and 11
Trial: NCT01811277
Drug: SOX sequential S-1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4-6 cycles SOX followed by S-1 monotherapy until disease progression~S-1: 40\~60mg bid，po, d1\~14 （S-1：BSA \<1.25m2, 40mg bid, 1.25m2≤BSA≤1.5m2,50mg bid, BSA\>1.5m2, 60mg bid） oxaliplatin：130mg/m2，iv drip for 2h，d1
Trial: NCT01725477
Drug: methylen blue &normal saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Washing after dye injection
Trial: NCT00626925
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo (12 weeks during which the dosage of study medication is gradually increased up to 200 mg orally and then maintained, and 1 week of medication taper)
Trial: NCT01381484
Drug: 10% Argireline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10% Argireline (La jolie gel®, Pacific health care, Thailand) were instructed to apply the gel over the face and periorbital area twice daily for a period of 3 months.
Trial: NCT03378661
Drug: E1224 Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: E1224 matched placebo capsules
Trial: NCT05433428
Drug: Preservative Free
RxNorm normalized name: preservative free
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preservative free eye drops
Trial: NCT01871142
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mL
Trial: NCT00942448
Drug: Diclofenac HPBCD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 single injection at day of dental surgical extraction
Trial: NCT01072383
Drug: placebo treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: administration of the end formulation buffer of BT061 without active ingredient, either subcutaneous or intravenous
Trial: NCT00002895
Drug: chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01829477
Drug: TAK-875 Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAK-875 placebo-matching tablets
Trial: NCT01953497
Drug: URC102
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00478946
Drug: (FOLPI) Picoplatin with 5-FU and Leucovorin
RxNorm normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Picoplatin, 150 mg/m2, 5-FU and leucovorin (q 4 weeks, Schedule B). Leucovorin, 400 mg/m2 in D5W and leucovorin (± picoplatin) will be followed by a 5-FU bolus of 400 mg/m2 and then by 5-FU, 2,400 mg/m2 in D5W administered as a 46-hour continuous infusion.
Trial: NCT00478946
Drug: FOLFOX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxaliplatin 85 mg/m. Leucovorin (400 mg/m2 in D5W). Oxaliplatin and leucovorin Leucovorin + oxaliplatin 5-FU bolus of 400 mg/m2 and then by 5-FU, 2400 mg/m2 in D5W administered as a 46-hour continuous infusion.
Trial: NCT01215942
Drug: LY2127399
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered Subcutaneously
Trial: NCT00198081
Drug: COX-2 Inhibitor 6-8 weeks prior to surgery
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg BID 6-8 weeks prior to surgery
Trial: NCT00198081
Drug: COX-2 Inhibitor for 6 months prior to follow-up EUS or ERCP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg BID for 6 months prior to follow-up EUS or ERCP
Trial: NCT03896217
Drug: Simvastatin
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Simvastatin 40mg for first 4 weeks and 80mg (if tolerated) thereafter up to 17 weeks
Trial: NCT01890746
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orally, once daily, beginning on Day 4 of the first cycle of induction. After 7 days, the dose given was matching 300 mg Eltrombopag if platelet counts were \<100 Gi/L. Placebo continued until achievement of platelet count of at least 200 Gi/L or assessment of remission of bone marrow status or a maximum of 42 days after initiation of most recent induction. In subjects of East Asian heritage placebo matching 100 mg Eltrombopag orally once daily was used and after 7 days, the placebo matching 150 mg Eltrombopag was given if platelet counts were \<100 Gi/L.
Trial: NCT02448459
Drug: COOL-COS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Controlled ovarian stimulation will start on the second or third day of a menstrual cycle: Oral clomiphene citrate: 100 mg/day until the day of the triggering. Oral letrozole: 7.5 mg/day during the first 5 days of the controlled ovarian stimulation.~Corifollitropin Alfa: 100 mcg on the 3rd day of the controlled ovarian stimulation.~The triggering will be performed using leuprorelin 1 mg (subcutaneous).
Trial: NCT01525589
Drug: PM01183
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PM01183 drug product (DP) is presented as a lyophilized powder for concentrate for solution for infusion with two strengths: 1 mg/vial and 4 mg/vial
Trial: NCT00751374
Drug: gentamicin
RxNorm normalized name: Gentamicin
DrugBank: Gentamicin (DB00798)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: topical gentamicin cream on daily basis
Trial: NCT00751374
Drug: gentamicin cream alternating with mupirocin cream
RxNorm normalized name: mupirocin Topical Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: topical gentamicin cream alternating with mupirocin cream at monthly basis
Trial: NCT02167464
Drug: Renin treatment-guided Therapeutics
RxNorm normalized name: Moisturel Therapeutic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients are treated based upon their renin levels according to an approved algorithm.
Trial: NCT01701921
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sugar pill designed to mimic pregabalin capsule, by mouth one hour before surgery
Trial: NCT00686036
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03831633
Drug: Standard of Care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: * oral aprepitant 125mg (Day 1) and 80mg daily (on Day 2 and Day 3)~* IV ondansetron 8 mg on Day 1~* Dexamethasone 12 mg on Day 1 and 8 mg daily from Day 2 to Day 4
Trial: NCT00751166
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo once daily for 28 days
Trial: NCT01031706
Drug: Hypertonic Saline
RxNorm normalized name: ENTSOL Hypertonic Saline Nasal Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: inhaled HS (6% NaCl, 4mL) three times a day for 28 days
Trial: NCT01031706
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 ml 0.12% NaCl inhaled three times a day x 28 days
Trial: NCT01185288
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Methotrexate capsule
Trial: NCT01505465
Drug: Melatonin
RxNorm normalized name: Melatonin
DrugBank: Melatonin (DB01065)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 5mg of melatonin will be taken by the subject for 3 nights prior and continuing 3 nights after surgery as tolerated.
Trial: NCT01505465
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5mg of placebo will be taken by the subject 3 nights prior to surgery and continuing 3 nights after surgery
Trial: NCT00679783
Drug: AZD2281
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PARP inhibitor Olaparib tablets, oral
Trial: NCT01364077
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matched placebo
Trial: NCT03009500
Drug: Depo-Medrol Injectable Product
RxNorm normalized name: DEPO-Medrol Injectable Product
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00437320
Drug: Metvix Cream 160 mg/g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants were treated with topical administration of Metvix cream.
Trial: NCT00437320
Drug: Metvix Vehicle Group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants were treated with topical administration of Metvix Vehicle cream.
Trial: NCT02876302
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 60 mg/m2, IV (in the vein) every 14 days for 4 doses.
Trial: NCT02876302
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 600 mg/m2, IV (in the vein) every 14 days for 4 doses.
Trial: NCT03860233
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal spray to mimic Oxytocin intranasal spray
Trial: NCT04318678
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide is a nitrogen mustard derivative. It acts as an alkylating agent that causes cross-linking of DNA strands by binding with nucleic acids and other intracellular structures, thus interfering with the normal function of DNA.
Trial: NCT00878670
Drug: EPOGAM 1000
RxNorm normalized name: Epogam
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One capsule of EPOGAM 1000 contains 932-1073 mg Oenothera seminis oleum, equivalent to 80 mg gamma-linolic acid. Children (2-12 years) take 2 capsules in the morning and evening, whereas persons over 12 years take 3 capsules in the morning and evening. The duration of the treatment is 12 weeks.
Trial: NCT00901368
Drug: FOSTER
RxNorm normalized name: Foster and Thrive Biotin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CHF1535 (beclometasone dipropionate 100 µg plus formoterol 6 µg) pMDI aerosol via HFA-134a propellant 2 inhalations b.i.d. (daily dose 400 µg + 24µg)
Trial: NCT01457820
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matched placebo, stat dose, then 5 days of matched placebo BD.
Trial: NCT03928158
Drug: LCZ 696
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50-100-200 mg tablet
Trial: NCT03949842
Drug: Inhaled corticosteroids/long-acting beta2-adrenergic/long-acting muscarinic receptor antagonists
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A fixed dose of combination ICS/LABA plus LAMA once-daily was administered to COPD subjects using two separate non-ELLIPTA devices.
Trial: NCT00762671
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo 1 po BID for 2 weeks
Trial: NCT01845142
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03441269
Drug: Oral Ibuprofen
RxNorm normalized name: ibuprofen Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Ibuprofen will be given to all the arms; only the dosage will be different: 400mg vs. 600mg vs. 800mg
Trial: NCT03971123
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo to AC-SD-03 50g of AC-SD-03P mixed in 240mL dosing liquid at Hour 0 Day 1
Trial: NCT02848170
Drug: CS-3150
RxNorm normalized name: MyoGesic-CS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CS-3150 2.5mg, oral
Trial: NCT01224964
Drug: long acting beta2 mimetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ICS+long acting beta2 agonist: twice daily
Trial: NCT01975961
Drug: Crestor 20mg(Rosuvastatin 20mg), Micardis 80mg(Telmisartan 80mg) , FDC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: For co-administration, Crestor 1 tablet and Micardis 1 tablet. For FDC administration, FDC 1 tablet.
Trial: NCT02633501
Drug: P03277
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single intravenous (IV) bolus injection at a rate of 2 mL/second
Trial: NCT02093689
Drug: Part 2 Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo drug product is a sterile, clear colorless liquid, free from particulates of foreign matter. Each vial contains a nominal 4.5 mL of solution containing 20 mM sodium citrate buffer (pH 6.3 ± 0.5). For administration to patients, 4.0 mL of the drug product is added to a 500-mL bottle of commercially available irrigation solution.
Trial: NCT04479657
Drug: QingFei Granule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: QingFei Granule is made from 6 commonly herbal medicine granule, such as Jingjie,Huang Qin,Lianqiao,etc. The children were given one package of QingFei Granule every day, dividing into 3 times to be administrated. It's be given for 5 days.
Trial: NCT03131999
Drug: Placebo - Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sirolimus or everolimus will be withdrawn after 28 days if used at baseline
Trial: NCT01898910
Drug: Optimal medial therapy (OMT)
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiarrhythmic and antihypertensive therapy will be administered according to the guidelines
Trial: NCT02149875
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 ml saline intravenous infusion once daily for 10 days.
Trial: NCT01032174
Drug: Azithromycin SR
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Azithromycin SR, 2.0 g by mouth (PO) x 1
Trial: NCT01032174
Drug: Amoxiclav 1000 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxiclav 1000 mg x twice daily, 10 days
Trial: NCT00166465
Drug: ALIMTA plus Oxaliplatin versus Oxaliplatin plus 5-Fluorouracil and Leucovorin (FOLFOX 4 Regimen)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04499248
Drug: AGN-193408 SR
RxNorm normalized name: VITEX AGNUS-CASTUS WHOLE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: An implant containing preservative-free AGN-193408 dispersed in a biodegradable polymer matrix. Implants are preloaded into an applicator to facilitate insertion of the implant into the anterior chamber of the study eye.
Trial: NCT04499248
Drug: AGN-193408 SR
RxNorm normalized name: VITEX AGNUS-CASTUS WHOLE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: An implant containing preservative-free AGN-193408 dispersed in a biodegradable polymer matrix. Implants are preloaded into an applicator to facilitate insertion of the implant in the study eye.
Trial: NCT03624244
Drug: Aromatase Inhibitors
RxNorm normalized name: Aromatase inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maintenance of AI versus interruption of AI
Trial: NCT03943173
Drug: Chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given standard chemotherapy
Trial: NCT00131235
Drug: Sulfadoxine-pyrimethamine every 4 weeks + azithromycin twice
RxNorm normalized name: Fansidar 500/25 (sulfadoxine / pyrimethamine) Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sulfadoxine-pyrimethamine, 3 tablets (each containing 500mg of sulfadoxine and 25mg of pyrimethamine), taken once at antenatal care enrolment (14.0-25.9 gestation weeks) and then at 4 week intervals until 37.0 gestation weeks.~2 azithromycin tablets (each 500 mg) taken once at antenatal care enrolment (14.0-25.9 gestation weeks) and another time between 28.0 and 33.9 gestation weeks.
Trial: NCT00239395
Drug: Meloxicam ampoule
RxNorm normalized name: Meloxicam
DrugBank: Meloxicam (DB00814)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00239395
Drug: Meloxicam tablet
RxNorm normalized name: Meloxicam Tablets
DrugBank: Meloxicam (DB00814)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03961464
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose
Trial: NCT01922050
Drug: LEO 43204 Formulation 1
RxNorm normalized name: Leo-K
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01922050
Drug: LEO 43204 Formulation 2
RxNorm normalized name: Hep B, unspecified formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01922050
Drug: LEO 43204 Formulation 1 Dose Y
RxNorm normalized name: Y
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01922050
Drug: LEO 43204 Formulation 2 Dose XX
RxNorm normalized name: Hep B, unspecified formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02805972
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1 ml
Trial: NCT03099356
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide 100 mg, PO, days 1-5 and 15-19
Trial: NCT02322528
Drug: Administration of Lotemax
FDA approved: no
EMA approved: no
PMDA approved: no
Description: An FDA approved drug (Lotemax) will be administered to induce an inflammatory mediated response in both eyes.
Trial: NCT00496509
Drug: ZD6474 (Zactima) 100mg
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00496509
Drug: ZD6474 (Zactima) 300mg
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02127047
Drug: Exercise
RxNorm normalized name: Tenscare ITouch Sure Pelvic Floor Exerciser
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03496870
Drug: Carbidopa Levodopa
RxNorm normalized name: carbidopa / levodopa
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levodopa: dopamine precursor Carbidopa: DOPA decarboxylase inhibitor
Trial: NCT03211871
Drug: Normal Saline Flush, 0.9% Injectable Solution_#1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraoperative intravenous normal saline infusion
Trial: NCT02345226
Drug: FTC/RPV/TAF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200/25/25 mg FDC tablets administered orally once daily
Trial: NCT02345226
Drug: EFV/FTC/TDF Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets administered orally once daily
Trial: NCT02345226
Drug: EFV/FTC/TDF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600/200/300 mg FDC tablets administered orally once daily
Trial: NCT01133821
Drug: IPSRT plus placebo (IPSRT-PLA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will be seen approximately weekly/biweekly during the 20 week acute phase. All subjects will return at weeks 36 and 52 for follow-up assessments to evaluate the enduring effects of treatment.~The therapist will administer IPSRT and the psychiatrist will administer medication management procedures (quetiapine or placebo).~Medication Dosing~The research pharmacy will dispense medication in the following unit-dose packs:~Dose A (50 mg of QUE or PLA) Dose B (100 mg of QUE or PLA) Dose C (separate packs of 50 mg and 100 mg QUE capsules or PLA) Dose D (200 mg of QUE or PLA) Dose E (separate packs of 50 mg and 200 mg QUE capsules or PLA) Dose F (separate packs of 100mg and 200mg QUE capsules or PLA)
Trial: NCT02345226
Drug: FTC/RPV/TAF Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets administered orally once daily
Trial: NCT03239600
Drug: GSK2618960 2 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK2618960 solution for injection, 100mg/mL is clear to opalescent, colorless to yellow or pale brown liquid.
Trial: NCT03239600
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo solution will be administered by IV infusion.
Trial: NCT03239600
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: MTX dose between 7.5 to 15 mg will be administered in tablet form once in a week till last dose of GSK2618960 to all subjects in Part I and Part II.
Trial: NCT04356742
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dapagliflozin Placebo, orally, once daily, up to 24weeks